TruScreen Group (TRU) H2 2026 earnings summary

Executive summary

• FY26 annual sales reached NZD $2.4m, representing 42% year-over-year growth, with revenue up 33% year-over-year.

• Expansion into new markets with distributor appointments in South Africa, Uzbekistan, Bangladesh, Romania, and Italy, and re-entry into India and Indonesia.

• Major public health programs launched, including a 260,000-woman screening initiative in Vietnam and re-entry into India.

• Landmark clinical studies published, confirming high sensitivity and accuracy of the screening device, including use in pregnant women.

• UNITAID proposals submitted, targeting 14 high-burden countries with up to US $18.4m potential revenue and a 1 billion women market.

Financial highlights

• FY26 sales increased 42% year-over-year to NZD $2.4m; revenue up 33% year-over-year.

• Gross margin improved to 31.5% in FY2026 from 30.1% in FY2025.

• Net loss for the year was $2.25m, slightly higher than $2.24m in FY2025.

• Net assets rose 160% year-over-year to NZD $2.6m.

• China accounted for 61.3% of FY26 sales, with Zimbabwe at 22.4%, and new contributions from India and Indonesia.

Outlook and guidance

• FY27 growth driven by anticipated regulatory approvals in India and South Africa, and commercial launches in Indonesia and Uzbekistan.

• Gross margin expected to rise above FY26's 31.5% due to favorable country mix.

• National expansion planned in Vietnam and further scale-up in Uzbekistan.

• UNITAID funding decisions and new market activations expected in H2 CY2026.

• Anticipates significant growth from public screening programs and new market entries.